Mechanisms of hypertension associated with BAY 43-9006.

PURPOSE BAY 43-9006 (sorafenib) is an inhibitor of Raf kinase, the vascular endothelial growth factor (VEGF) receptor-2, and angiogenesis in tumor xenografts. The current study investigated the incidence, severity, and mechanism of blood pressure (BP) elevation in patients treated with BAY 43-9006. PATIENTS AND METHODS Twenty patients received BAY 43-9006 400 mg orally twice daily. BP and heart rate were measured at baseline and then every 3 weeks for 18 weeks. VEGF, catecholamines, endothelin I, urotensin II, renin, and aldosterone were measured at baseline and after 3 weeks of therapy. We assessed vascular stiffness at baseline, after 3 to 6 weeks of therapy, and again after 9 to 10 months of therapy. RESULTS Fifteen (75%) of 20 patients experienced an increase of > or = 10 mmHg in systolic BP (SBP), and 12 (60%) of 20 patients experienced an increase of > or = 20 mmHg in SBP compared with their baseline value, with a mean change of 20.6 mmHg (P < .0001) after 3 weeks of therapy. There were no statistically significant changes in humoral factors, although there was a statistically significant inverse relationship between decreases in catecholamines and increases in SBP, suggesting a secondary response to BP elevation. Measures of vascular stiffness increased significantly during the period of observation. CONCLUSION Treatment with BAY 43-9006 is associated with a significant and sustained increase in BP. The lack of significant change in circulating factors suggests that these humoral factors had little role in the increase in BP.

[1]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[2]  Mario Fritsch Neves,et al.  Endothelium-Restricted Overexpression of Human Endothelin-1 Causes Vascular Remodeling and Endothelial Dysfunction , 2004, Circulation.

[3]  Tim Eisen,et al.  Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[4]  M. Ratain,et al.  Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[6]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[7]  D. Stupack,et al.  Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli , 2003, Science.

[8]  H. Struijker‐Boudier,et al.  Current Perspectives on Arterial Stiffness and Pulse Pressure in Hypertension and Cardiovascular Diseases , 2003, Circulation.

[9]  U. Vanhoefer,et al.  Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. , 2003, Seminars in oncology.

[10]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[11]  S. Douglas,et al.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. , 2000, Trends in cardiovascular medicine.

[12]  A. Siebenhofer,et al.  The reproducibility of central aortic blood pressure measurements in healthy subjects using applanation tonometry and sphygmocardiography , 1999, Journal of Human Hypertension.

[13]  D. Webb,et al.  Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis , 1998, Journal of hypertension.

[14]  H. Granger,et al.  VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. , 1998, American journal of physiology. Heart and circulatory physiology.

[15]  A C Shore,et al.  Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. , 1997, The Journal of clinical investigation.

[16]  A. Greene,et al.  Rapid microvessel rarefaction with elevated salt intake and reduced renal mass hypertension in rats. , 1996, Circulation research.

[17]  C. Vlachopoulos,et al.  Medial necrosis and acute alterations in aortic distensibility following removal of the vasa vasorum of canine ascending aorta. , 1993, Cardiovascular research.

[18]  H. Struijker‐Boudier,et al.  The Microcirculation and Hypertension , 1992 .

[19]  R. Prewitt,et al.  Attenuation of the microcirculation in young patients with high-output borderline hypertension. , 1983, Hypertension.

[20]  J. Koch-weser,et al.  Correlation of pathophysiology and pharmacotherapy in primary hypertension. , 1973, The American journal of cardiology.

[21]  D. Sane,et al.  Angiogenic growth factors and hypertension , 2004, Angiogenesis.

[22]  G. Lip,et al.  Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. , 2003, American journal of hypertension.

[23]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .